Intercept Pharmaceuticals, Inc. – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 09/30/23 Q3

ended 06/30/23 Q2

ended 03/31/23 Q1

ended 12/31/22 FY 2022

ended 09/30/22 Q3

Prospectuses and Registrations Filter

Securities registration termination

Removal from listing

Updated info for already-effective prospectus

Updated info for already-effective prospectus

Updated info for already-effective prospectus

Ownership Filter

Akkaraju Srinivas

Berrey M Michelle

Richardson Linda M

News Filter

Re: Notice of Supplemental Indenture and Make-Whole Fundamental Change

Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 Per Share in Cash, Expanding the Global Footprint of Alfasigma via a Leader in Rare and Serious Liver Diseases

Reports Second Quarter 2023 Financial Results and Provides Business Updates

Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses

Receives Complete Response Letter From FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis Due to NASH

Proxies Filter

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Other Filter

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Scanned paper annual report submission

Confidential treatment order